Abstract:Intravenous saline solutions were first introduced into clinical practice in the Sunderland cholera epidemic of 1831 [1]. More than 150 years later, not only is 0.9 % saline the most commonly used intravenous fluid in critically ill patients, it is also the fluid that has been administered to the largest number of critically ill patients in randomised controlled trials [2,3]. It is cheap and readily available, and more than a million litres of intravenous 0.9 % saline are administered to patients around the wo… Show more
“…However, the association between the development and accentuation of AKI and 0.9% saline administration in critically ill patients remains controversial, with data both supporting and rejecting the hypothesis [ 19 , 20 ]. A recent study failed to demonstrate a benefit of Plasma-Lyte on the incidence of AKI, but the mean fluid volume administered was only 2 L in 24 h, considerably less than in our study [ 10 ].…”
Section: Discussioncontrasting
confidence: 87%
“…A 0.9% saline solution remains the most widely used intravenous fluid during the perioperative period, but recent data has emerged questioning its safety [ 6–8 ]. A 0.9% saline solution has been shown to reduce renal cortical blood flow in healthy volunteers [ 9 ], and animal studies have suggested that sustained renal vasoconstriction is specifically related to hyperchloraemia [ 10 ]. The high chloride load in 0.9% saline has also been shown to induce hyperchloraemic acidosis [ 11 ], and this in turn has been associated with the development and accentuation of postoperative AKI [ 12 ].…”
BackgroundKidney transplant recipients often receive large volumes of intravenous fluid replacement in the peri-operative period. Administration of 0.9% saline has previously been associated with acidosis, hyperkalaemia and acute kidney injury. The perioperative use of physiologically balanced replacement fluids may reduce the incidence of post-operative renal replacement therapy and hyperkalaemia.MethodsA retrospective review of consecutive renal transplants before and after a change in perioperative fluid prescription from 0.9% saline to Plasma-Lyte 148.ResultsA total of 97 patients were included in the study, 59 receiving exclusively 0.9% saline and 38 receiving exclusively Plasma-Lyte. Patients in the Plasma-Lyte group were less likely to require emergency postoperative dialysis than those receiving 0.9% saline [odds ratio (OR) 0.15 (95% confidence interval 0.03–0.48), P = 0.004], and these patients had more favourable biochemical parameters with less hyperkalaemia, less acidosis and better diuresis. Patients in the Plasma-Lyte group also had a shorter length of hospital stay (7 days versus 11 days; P < 0.0001) and better graft function at 3 months postoperatively (estimated glomerular filtration rate 51 versus 44 mL/min/1.73 m2; P = 0.03); however, there was no difference in graft function at 1 year.ConclusionsPlasma-Lyte in the perioperative period is safe in renal transplantation and is associated with a favourable biochemical profile, including a reduced incidence of hyperkalaemia, better diuresis and less frequent use of renal replacement therapy early after surgery. In patients receiving Plasma-Lyte, graft function was better at 3 months, but this difference did not persist up to 1 year after transplantation.
“…However, the association between the development and accentuation of AKI and 0.9% saline administration in critically ill patients remains controversial, with data both supporting and rejecting the hypothesis [ 19 , 20 ]. A recent study failed to demonstrate a benefit of Plasma-Lyte on the incidence of AKI, but the mean fluid volume administered was only 2 L in 24 h, considerably less than in our study [ 10 ].…”
Section: Discussioncontrasting
confidence: 87%
“…A 0.9% saline solution remains the most widely used intravenous fluid during the perioperative period, but recent data has emerged questioning its safety [ 6–8 ]. A 0.9% saline solution has been shown to reduce renal cortical blood flow in healthy volunteers [ 9 ], and animal studies have suggested that sustained renal vasoconstriction is specifically related to hyperchloraemia [ 10 ]. The high chloride load in 0.9% saline has also been shown to induce hyperchloraemic acidosis [ 11 ], and this in turn has been associated with the development and accentuation of postoperative AKI [ 12 ].…”
BackgroundKidney transplant recipients often receive large volumes of intravenous fluid replacement in the peri-operative period. Administration of 0.9% saline has previously been associated with acidosis, hyperkalaemia and acute kidney injury. The perioperative use of physiologically balanced replacement fluids may reduce the incidence of post-operative renal replacement therapy and hyperkalaemia.MethodsA retrospective review of consecutive renal transplants before and after a change in perioperative fluid prescription from 0.9% saline to Plasma-Lyte 148.ResultsA total of 97 patients were included in the study, 59 receiving exclusively 0.9% saline and 38 receiving exclusively Plasma-Lyte. Patients in the Plasma-Lyte group were less likely to require emergency postoperative dialysis than those receiving 0.9% saline [odds ratio (OR) 0.15 (95% confidence interval 0.03–0.48), P = 0.004], and these patients had more favourable biochemical parameters with less hyperkalaemia, less acidosis and better diuresis. Patients in the Plasma-Lyte group also had a shorter length of hospital stay (7 days versus 11 days; P < 0.0001) and better graft function at 3 months postoperatively (estimated glomerular filtration rate 51 versus 44 mL/min/1.73 m2; P = 0.03); however, there was no difference in graft function at 1 year.ConclusionsPlasma-Lyte in the perioperative period is safe in renal transplantation and is associated with a favourable biochemical profile, including a reduced incidence of hyperkalaemia, better diuresis and less frequent use of renal replacement therapy early after surgery. In patients receiving Plasma-Lyte, graft function was better at 3 months, but this difference did not persist up to 1 year after transplantation.
“…Additional considerations were that the sodium in Hartmann solution contains calcium and was therefore incompatible with blood products preserved in citrate-based anticoagulation solutions, and that Hartmann solution contains more chloride than PL-148. 14 The composition of the study fluids is shown in eTable 1 in Supplement 2. Participating ICUs were assigned to use blinded study fluid (either saline or buffered crystalloid) for alternating treatment blocks of 7 weeks, with the initial fluid determined by the study statistician using computer-generated randomization.…”
Section: Study Randomization and Treatmentmentioning
“…Although some balanced solutions are calcium-free (i.e., Plasma-Lyte and Normosol-R), there are others that contain calcium such as Lactated Ringer's, which has a calcium concentration of 2 mmol/L (8 mg/dL) (Young & Joannidis, 2014). As long as the calcium concentration of the solution is less than the patient's serum calcium concentration, the solution can still be expected to lower calcium levels over …”
The most common cause of hypercalcemia in the emergency department (ED) is malignancy-associated hypercalcemia (MAH), which can be caused by direct bone resorption from bone metastases, vitamin D secreting malignancies, and increased parathyroid hormone (PTH) or PTH-related protein (PTHrP) levels. Malignancy-associated hypercalcemia is associated with a very poor prognosis, with half of the patients dying within a month of diagnosis. Management consists of adequate hydration, bisphosphonate therapy, and correction of other abnormal electrolyte levels. Currently, no therapies have demonstrated an effect on mortality and are therefore viewed only as a means of stabilizing the patient until the underlying condition can be treated. All MAH patients should receive an oncology consult as soon as possible so they are able to receive treatment for the causative malignancy and increase their chance of survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.